EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality worldwide, with nearly one quarter of patients presenting with metastatic disease at diagnosis. The epidermal growth factor receptor (EGFR) plays a central role in CRC pathogenesis through activation of downstream RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways, and has become a major therapeutic target. Anti-EGFR monoclonal antibodies, cetuximab and panitumumab, have demonstrated survival benefit in selected patients, particularly those with left-sided, RAS wild-type tumors. However, primary and acquired resistance limit their efficacy, underscoring the need for predictive biomarkers and novel strategies. This review synthesizes current knowledge of EGFR biology, therapeutic integration, and biomarker development, including RAS and BRAF mutations, MSI status, HER2 amplification, EGFR ligands (AREG/EREG), consensus molecular subtypes, and liquid biopsy applications. We also discuss mechanisms of resistance such as pathway reactivation, receptor mutations, and epithelial-to-mesenchymal transition, alongside emerging approaches, including combination regimens, ctDNA-guided rechallenge, and genotype-specific inhibitors. Collectively, these insights highlight the evolving landscape of precision oncology in CRC and the importance of molecular stratification to optimize EGFR-targeted therapy and overcome resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remaining trials evaluated trastuzumab with lapatinib/pertuzumab/tucatinib, which also showed responses to HER2-positive mCRC [33,80].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35,36,37].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Studies such as CRICKET and CAVE showed that restarting the same therapy in carefully selected patients can lead to increased overall survival and ORR [33].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Beyond bypass loops, mutations in the extracellular domain of EGFR (EGFR-ECD mutation), such as the S492R mutation, can change the receptor shapes, which in turn prevents cetuximab binding [33,34].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“The CRYSTAL trial highlighted that the combination of cetuximab with FOLFIRI improved PFS and overall response rate [33].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064 · cited 1×
“Colorectal cancer (CRC) ranks third in incidence with 1.9 million new cases, and ranks third in mortality during the year 2022, and around 24% of the cases present with de novo metastatic disease [1–3].”
InfluentialEpithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628 · cited 1×
“EMT is a complicated process where epithelial cells transform and acquire mesenchymal characteristics [99,100].”
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“CMS2 (canonical/epithelial) tumors, characterized by WNT and MYC pathway activation, are highly EGFR dependent and consistently derive substantial benefit from anti-EGFR therapy [69,70].”
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“The pivotal BOND trial demonstrated improved response rates and survival with cetuximab [33], while early panitumumab studies confirmed activity in heavily pretreated patients [34].”
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 4×
“…and progression-free survival (PFS) (median PFS, 8.9 vs. 8.0 months; hazard ratio, 0.85; 95% CI, 0.72 to 0.99; p = 0.048) compared to FOLFIRI alone [5], while the PRIME trial demonstrated that panitumumab plus FOLFOX significantly prolonged PFS over FOLFOX alone (median PFS, 9.6 vs. 8.0 months;…”
InfluentialVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288 · cited 1×
“These receptors mediate changes in vascular proliferation and permeability [120].”
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060 · cited 1×
“Colorectal cancer (CRC) ranks third in incidence with 1.9 million new cases, and ranks third in mortality during the year 2022, and around 24% of the cases present with de novo metastatic disease [1–3].”
InfluentialOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · cited 1×
“Their high mutational burden and frequent subclonal resistance drivers make immune checkpoint inhibitors the preferred option, positioning MSI status as a strong negative predictive biomarker [55].”
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“This mutation leads to activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which results in uncontrollable cell proliferation [95] (Figure 2).”
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“The CRYSTAL and PRIME trials are the first randomized trials to demonstrate the efficacy of the anti-EGFR antibodies cetuximab and panitumumab in the treatment of metastatic CRC (mCRC) and have led to improved survival outcomes [5,6].”
Cohen, S. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)83739-0 · Cited by 2,193
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058 · cited 1×
“This is often EGFR-independent and therefore does not respond to EGFR inhibition [96].”
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 1×
“These proteins play significant roles in EGFR-related signaling pathways [87,88].”
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“…8.0 months; hazard ratio, 0.85; 95% CI, 0.72 to 0.99; p = 0.048) compared to FOLFIRI alone [5], while the PRIME trial demonstrated that panitumumab plus FOLFOX significantly prolonged PFS over FOLFOX alone (median PFS, 9.6 vs. 8.0 months; hazard ratio, 0.80; 95% CI, 0.66 to 0.97; p = 0.02) [35].”
InfluentialCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · cited 1×
“Since the presence of RAS mutations is the most well-established predictor of lack of response, their routine testing is essential prior to starting therapy [8–10].”
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“The mechanisms of acquired resistance are the following: Acquired mutations in the RAS/RAF signaling pathway: In addition to their role in primary resistance, KRAS mutations constitute 50% of acquired resistance cases [106].”
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 3×
“Doublet therapy with encorafenib and cetuximab also improved survival (median OS 8.4 months) relative to control [42].”
InfluentialERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475 · cited 1×
“The RAS/RAF/MAPK/ERK pathway plays a crucial role in tumor cell survival and development, with ERK influencing tumor proliferation, invasion, metastasis, extracellular matrix degradation, and angiogenesis [20].”
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
Yu, H. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1472 · Cited by 1,424 · cited 1×
“Upon its binding to its ligand, and activation of the RAS / RAF /MAPK and PI3K/AKT pathways takes place [108,109].”
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423 · cited 1×
“The activation of this receptor launches a cascade of intracellular signaling pathways, including the PI3K/AKT, RAC1/cell division control protein 42 (CDC42), driving cell proliferation and survival [113] (Figure 2).”
Review of epidermal growth factor receptor biology
Herbst, R. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.041 · Cited by 1,390 · cited 2×
“The Biology EGFR is a transmembrane glycoprotein involved in cellular proliferation, differentiation, and survival [12].”
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233 · cited 1×
“Loss-of-function mutations to PTEN or activating mutations in PIK3CA , present in 10–20% of CRC cases, result in unchecked pathway activation [24].”
A comprehensive pathway map of epidermal growth factor receptor signaling
Oda, K., Matsuoka, Y., Funahashi, A., & Kitano, H. (2005) · Molecular Systems Biology · doi:10.1038/msb4100014 · Cited by 1,158
Signaling through the JAK/STAT pathway, recent advances and future challenges
Kisseleva, T., Bhattacharya, S., Braunstein, J., & Schindler, C. W. (2002) · Gene · doi:10.1016/s0378-1119(02)00398-0 · Cited by 1,154 · cited 1×
“It significantly promotes tumor formation, blood vessel growth, tissue invasion, metastasis, and immune evasion [98].”
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059 · cited 1×
“In contrast, during EMT, tumor cells undergo transcriptional reprogramming that reduces EGFR reliance and activates bypass pathways such as MET, TGF β , PI3K, and stromal interactions [102].”
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941 · cited 1×
“Certain alterations in EGFR and EGFR-specific ligands that result in primary (inherent) resistance have been identified in recent years [85,86].”
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 1×
“Bertotti et al. analyzed the genotype-response correlations in mCRC xenografts and found that HER2 gene amplification was specifically related to cetuximab resistance, and that this resistance can be overcome by administration of a HER2 inhibitor [115] (Figure 2).”
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775 · cited 1×
“Multiple trials have shown that patients with KRAS exon 2 mutations do not respond properly to anti-EGFR therapy [91,92].”
Phosphotyrosine interactome of the ErbB‐receptor kinase family
Schulze, W. X., Deng, L., & Mann, M. (2005) · Molecular Systems Biology · doi:10.1038/msb4100012 · Cited by 753 · cited 1×
“The phosphorylated EGFR then binds GRB2, which also binds to SOS, leading to a complex formation [21,22].”
Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709 · cited 4×
“They are typically microsatellite-stable, enriched for EGFR ligand expression (AREG/EREG), display CMS2 canonical subtype biology, and are more often RAS WT, which explains their greater dependence on EGFR signaling and superior response to anti-EGFR therapy when RAS / BRAF WT [38–40].”
InfluentialActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · cited 1×
“HER2 binding leads to activation of a signaling pathway common with that of EGFR, including the MAPK and PI3K/AKT pathways [114].”
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657 · cited 2×
“This mechanism is predominantly associated with acquired resistance following initial response to anti-EGFR therapy [145].”
Roock, W. D., Vriendt, V. D., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 603
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546 · cited 1×
“These aberrations may occur in RAS WT tumors and partially explain heterogeneous responses to cetuximab and panitumumab, with PIK3CA exon 20 mutations in particular being associated with reduced response and poorer outcomes [137].”
Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu378 · Cited by 540 · cited 1×
“However, expanded RAS testing to include KRAS exons 3 and 4 and NRAS exons 2, 3, and 4 revealed that approximately 15–20% of tumors classified as KRAS exon 2 WT harbor additional RAS mutations that similarly confer resistance [52].”
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527 · cited 1×
“The objective response rate (ORR) was 19% and 46%, the median duration of response (DOR) was 4.3 months and 7.6 months, and the median PFS was 5.6 months and 6.9 months, respectively [125].”
InfluentialKnowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · cited 2×
“Importantly, panitumumab binds to a different epitope on EGFR and retains activity against tumors harboring the S492R mutation, which explains why patients with this mutation may still respond to panitumumab but not cetuximab [116,119].”
PI3K/Akt/mTOR pathway as a target for cancer therapy
Morgensztern, D., & McLeod, H. L. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000173476.67239.3b · Cited by 468 · cited 1×
“Clinically, phosphorylated AKT has been consistently linked to poor prognosis across multiple malignancies, including CRC, highlighting its relevance as both a biomarker and therapeutic target [25].”
BRAF Mutation in Metastatic Colorectal Cancer
Tol, J., Nagtegaal, I. D., & Punt, C. J. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904160 · Cited by 445
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424 · cited 1×
“Studies such as CRICKET and CAVE show that this approach can improve ORR and OS [47,48].”
Siena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 422 · cited 1×
“Importantly, it is a positive predictor for HER2-targeted therapies such as trastuzumab deruxtecan, validated in DESTINY-CRC01 (NCT03384940) [63] and DESTINY-CRC02 (NCT04744831) [64].”
Ras Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 2×
“RAF then phosphorylates MEK, which in turn phosphorylates ERK, amplifying the signal and driving transcriptional programs that promote oncogenesis [23].”
Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes
Lee, M. S., Menter, D. G., & Kopetz, S. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0038 · Cited by 379
EGF receptor ligands: recent advances
Singh, B., Carpenter, G., & Coffey, R. J. (2016) · F1000Research · doi:10.12688/f1000research.9025.1 · Cited by 323 · cited 1×
“Seven EGFR ligands have been identified, including EGF, transforming growth factor-alpha (TGF-α ), amphiregulin (AREG), epiregulin (EREG), betacellulin, heparin-binding EGF, and epigen [18].”
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319 · cited 3×
“While RAS and BRAF V600E testing effectively excludes about 50% of patients from anti-EGFR therapy, a substantial proportion of RAS / BRAF WT patients still fail to respond [56].”
STAT‐mediated EGFR signaling in cancer
Quesnelle, K. M., Boehm, A. L., & Grandis, J. R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21475 · Cited by 295 · cited 1×
“Beyond these two important cascades, EGFR signaling also engages the JAK/STAT pathway, particularly STAT3 [26], which regulates transcription of genes involved in proliferation, angiogenesis, and immune evasion [27,28].”
Watanabe, J., Muro, K., Shitara, K., Yamazaki, K., Shiozawa, M., Ohori, H., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., et al. (2023) · JAMA · doi:10.1001/jama.2023.4428 · Cited by 280 · cited 1×
“The landmark PARADIGM trial (Japan, 2022) provided definitive evidence that in patients with RAS WT, left-sided mCRC, panitumumab plus mFOLFOX6 significantly improved overall survival (OS) compared with bevacizumab plus mFOLFOX6 (hazard ratio, 0.82; 95% CI 0.68–0.99; p = 0.031) [36].”
InfluentialEmergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271 · cited 2×
“For instance, mutations such as S492R, K467T, and R451C may respond to panitumumab, whereas G465E S464L, G465R, and I491M are associated with resistance [118,132].”
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · cited 1×
“For instance, mutations such as S492R, K467T, and R451C may respond to panitumumab, whereas G465E S464L, G465R, and I491M are associated with resistance [118,132].”
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231 · cited 1×
“%) patients, while no responses were observed in a matched real-world control cohort treated with standard salvage therapy [144].”
Boeckx, N., Koukakis, R., Op de Beeck, K., Rolfo, C., Van Camp, G., Siena, S., Tabernero, J., Douillard, J.-Y., André, T., & Peeters, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx119 · Cited by 217 · cited 1×
“Clinical efficacy is primarily observed in patients with left-sided, RAS wild-type (WT) tumors, but responses are often short-lived due to the development of secondary (acquired) resistance [5–7].”
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216 · cited 1×
“In contrast to melanoma, the use of BRAF inhibitors alone has yielded modest outcomes in CRC [128].”
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Leiphrakpam, P., & Are, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063178 · Cited by 193 · cited 1×
“These agents have not shown sufficient benefit to progress to successful phase III development in unselected CRC populations, underscoring the need for improved biomarker-driven patient selection and rational combination strategies [139].”
Buck, E., Eyzaguirre, A., Barr, S., Thompson, S., Sennello, R., Young, D., Iwata, K. K., Gibson, N. W., Cagnoni, P., & Haley, J. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0462 · Cited by 191 · cited 2×
“Buck et al. showed that CRC models maintaining a strict epithelial phenotype were 7-fold more sensitive to anti-EGFR treatment compared to those that had undergone EMT [101].”
Grasselli, J., Elez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T., Vidal, J., Garcia, M., Viéitez, J. M., Paéz, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx112 · Cited by 187 · cited 1×
“Importantly, ctDNA may detect resistance mutations present in metastatic sites but absent in the primary tumor, preventing futile anti-EGFR therapy [75,76].”
Sartore-Bianchi, A., Lonardi, S., Martino, C., Fenocchio, E., Tosi, F., Ghezzi, S., Leone, F., Bergamo, F., Zagonel, V., Ciardiello, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000911 · Cited by 185
Martinelli, E., Martini, G., Famiglietti, V., Troiani, T., Napolitano, S., Pietrantonio, F., Ciardiello, D., Terminiello, M., Borrelli, C., Vitiello, P. P., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2915 · Cited by 182 · cited 1×
“Studies such as CRICKET and CAVE show that this approach can improve ORR and OS [47,48].”
HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0568 · Cited by 176 · cited 2×
“Preclinical data support combined inhibition of EGFR and MET as a strategy to overcome this resistance pathway [146].”
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501912 · Cited by 166 · cited 3×
“Combination strategies such as encorafenib plus cetuximab ± binimetinib (BEACON trial) and encorafenib plus cetuximab with mFOL-FOX6(BREAKWATER trial) are reshaping treatment paradigms for this subgroup [42,43].”
InfluentialAcquired resistance to EGFR‐targeted therapies in colorectal cancer
Van Emburgh, B. O., Sartore-Bianchi, A., Di Nicolantonio, F., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160
Raghav, K., Siena, S., Takashima, A., Kato, T., Van den Eynde, M., Pietrantonio, F., Komatsu, Y., Kawakami, H., Peeters, M., Andre, T., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00380-2 · Cited by 155 · cited 2×
“Subgroup analysis did not show any difference between patients who are KRAS mutated and KRAS WT [64].”
Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4905 · Cited by 149 · cited 1×
“Bianco et al. observed that cetuximab-resistant cells secreted higher levels of VEGF and VEGFR1 than the parental cetuximab-sensitive cells [121].”
Bylsma, L. C., Gillezeau, C., Garawin, T. A., Kelsh, M. A., Fryzek, J. P., Sangaré, L., & Lowe, K. A. (2020) · Cancer Medicine · doi:10.1002/cam4.2747 · Cited by 133 · cited 3×
“They are typically microsatellite-stable, enriched for EGFR ligand expression (AREG/EREG), display CMS2 canonical subtype biology, and are more often RAS WT, which explains their greater dependence on EGFR signaling and superior response to anti-EGFR therapy when RAS / BRAF WT [38–40].”
Cremolini, C., Morano, F., Moretto, R., Berenato, R., Tamborini, E., Perrone, F., Rossini, D., Gloghini, A., Busico, A., Zucchelli, G., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx546 · Cited by 132 · cited 1×
“The PRESSING panel includes alterations in HER2 (amplification or activating mutations), MET amplification, NTRK / ROS1 / RET fusions, PIK3CA exon 20 mutations, PTEN inactivating alterations, AKT1 mutations, EGFR ectodomain (EGFR-ECD) mutations, and MAP2K1 mutations [57].”
Targeting STAT3 Signaling Pathway in Colorectal Cancer
Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2021) · Biomedicines · doi:10.3390/biomedicines9081016 · Cited by 128
Scartozzi, M., Bearzi, I., Pierantoni, C., Mandolesi, A., Loupakis, F., Zaniboni, A., Catalano, V., Quadri, A., Zorzi, F., Berardi, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5022 · Cited by 125 · cited 1×
“A strong association between the IGF-1R and EGFR pathway has been proven, as IGF-1R signaling has been shown to increase the activation of EGFR [110–112].”
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123 · cited 1×
“While these medications have improved survival in non-mutant KRAS WT mCRC, they are effective only in a subset of patients [56,82,83].”
Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma
Ma, X.-T. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i11.1569 · Cited by 120 · cited 2×
“STAT3 is a transcription factor upregulated in some cancers, including CRC [97].”
Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis
Wu, W. K. K., Wang, X., Cheng, A. S. L., Luo, M. X. M., Ng, S. S. M., To, K. F., Chan, F. K. L., Cho, C. H., Sung, J. J. �., & Yu, J. Q. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.009 · Cited by 115 · cited 1×
“Extensive crosstalk between these pathways enables compensatory signaling when one cascade is inhibited, representing a major mechanism of therapeutic resistance [30] (Figure 1).”
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 114 · cited 2×
“Aberrant EGFR signaling was strongly associated with the development of multiple cancers, including non-small cell lung cancer, CRC, pancreatic cancer, glioblastoma multiforme, and gastric cancer [14].”
Seligmann, J. F., Elliott, F., Richman, S. D., Jacobs, B., Hemmings, G., Brown, S., Barrett, J. H., Tejpar, S., Quirke, P., & Seymour, M. T. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6065 · Cited by 113 · cited 1×
“These EGFR ligands are frequently overexpressed in CRC, and their elevated expression correlates with improved outcomes following anti-EGFR treatment in RAS WT patients [65].”
Pietrantonio, F., Morano, F., Corallo, S., Miceli, R., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Bergamo, F., Sartore-Bianchi, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1467 · Cited by 113 · cited 1×
“Trials such as VALENTINO and PANAMA show that after an initial course of FOLFOX plus panitumumab, stopping oxaliplatin and continuing with fluoropy-rimidine (fluorouracil/leucovorin) plus panitimumab can help maintain disease control while reducing toxicity [45,46].”
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Napolitano, S., Martini, G., Ciardiello, D., Tufo, S. D., Martinelli, E., Troiani, T., & Ciardiello, F. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00479-x · Cited by 107 · cited 1×
“The epidermal growth factor receptor (EGFR) has a central role in promoting tumor growth, cell survival, and proliferation through downstream signaling pathways such as RAS/RAF/MEK/MAPK and the PI3K/AKT/mTOR pathways, and thus has emerged as a therapeutic target [4].”
Tosi, F., Sartore-Bianchi, A., Lonardi, S., Amatu, A., Leone, F., Ghezzi, S., Martino, C., Bencardino, K., Bonazzina, E., Bergamo, F., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.06.009 · Cited by 101 · cited 1×
“Median PFS was 4.7 months and median OS was 10.0 months, with one patient maintaining a complete response beyond 7 years of follow-up [142].”
InfluentialArena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5640 · Cited by 93 · cited 1×
“This antibody has shown a response in patients who developed resistance after treatment with anti-EGFR antibodies [149].”
Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01332 · Cited by 86 · cited 1×
“Trials such as VALENTINO and PANAMA show that after an initial course of FOLFOX plus panitumumab, stopping oxaliplatin and continuing with fluoropy-rimidine (fluorouracil/leucovorin) plus panitimumab can help maintain disease control while reducing toxicity [45,46].”
Bray, S. M., Lee, J., Kim, S. T., Hur, J. Y., Ebert, P. J., Calley, J. N., Wulur, I. H., Gopalappa, T., Wong, S. S., Qian, H.-R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51981-5 · Cited by 82 · cited 1×
“Lin et al. [103] demonstrated that Smad4 loss promotes EMT and attenuates cetuximab sensitivity, while Bray et al. [104] observed increased EMT markers at the time of acquired cetuximab resistance in patient samples.”
Johnsson, A., Hagman, H., Frödin, J., Berglund, Å., Keldsen, N., Fernebro, E., Sundberg, J., Christensen, R. D., Spindler, K.-L. G., Bergström, D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt236 · Cited by 77 · cited 1×
“In unselected patients, the use of erlotinib as maintenance treatment or the combination of lapatinib with capecitabine did not yield any significant results [133,134].”
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
Sickmier, E. A., Kurzeja, R. J. M., Michelsen, K., Vazir, M., Yang, E., & Tasker, A. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163366 · Cited by 76 · cited 2×
“Importantly, panitumumab binds to a different epitope on EGFR and retains activity against tumors harboring the S492R mutation, which explains why patients with this mutation may still respond to panitumumab but not cetuximab [116,119].”
Hu, Y. P., Patil, S. B., Panasiewicz, M., Li, W., Hauser, J., Humphrey, L. E., & Brattain, M. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0280 · Cited by 75 · cited 1×
“A strong association between the IGF-1R and EGFR pathway has been proven, as IGF-1R signaling has been shown to increase the activation of EGFR [110–112].”
Grb2 Is a Negative Modulator of the Intrinsic Ras-GEF Activity of hSos1
Zarich, N., Oliva, J. L., Martinez, N. J., Jorge, R., Ballester, A., Gutiérrez-Eisman, S., García-Vargas, S., & Rojas, J. M. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-12-1104 · Cited by 74 · cited 1×
“The phosphorylated EGFR then binds GRB2, which also binds to SOS, leading to a complex formation [21,22].”
Ciardiello, D., Martinelli, E., Troiani, T., Mauri, G., Rossini, D., Martini, G., Napolitano, S., Famiglietti, V., Tufo, S. D., Masi, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5635 · Cited by 69 · cited 1×
“Notably, patients without liver metastases experienced significantly longer PFS and OS, suggesting the metastatic site may influence benefit [122].”
Colorectal cancer in review: the role of the EGFR pathway
Saif, M. W. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003593962 · Cited by 67 · cited 1×
“In CRC, EGFR is frequently overexpressed, documented in 30–90% of advanced cases, and is associated with poor prognosis and inferior outcomes [12,16,17].”
Berlin, J., Neubauer, M., Swanson, P., Harker, W. G., Burris, H., Hecht, J. R., & Navale, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3548 · Cited by 65 · cited 1×
“The pivotal BOND trial demonstrated improved response rates and survival with cetuximab [33], while early panitumumab studies confirmed activity in heavily pretreated patients [34].”
EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Okada, Y., Kimura, T., Nakagawa, T., Okamoto, K., Fukuya, A., Goji, T., Fujimoto, S., Sogabe, M., Miyamoto, H., Muguruma, N., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0383 · Cited by 62 · cited 1×
“Tumors that fail to achieve sufficient receptor depletion after antibody binding often exhibit primary resistance [32].”
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61 · cited 1×
“Unlike static tissue assays, liquid biopsy offers minimally invasive sampling, captures tumor heterogeneity from multiple metastatic sites, enables real-time monitoring of molecular evolution, and allows serial assessments throughout therapy [72].”
The Evolving Treatment Landscape in BRAF-V600E–Mutated Metastatic Colorectal Cancer
Tabernero, J., Ros, J., & Élez, E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349561 · Cited by 59 · cited 2×
“BRAF V600E mutations, present in 8–12% of mCRC cases, are associated with poor prognosis and aggressive disease biology [41].”
Metzger, B., Chambeau, L., Begon, D. Y., Faber, C., Kayser, J., Berchem, G., Pauly, M., Boniver, J., Delvenne, P., Dicato, M. A., et al. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-144 · Cited by 56 · cited 1×
“At baseline, EGFR mutations in exons 18 to 21 occur at a frequency of 2.6%, 0.5%, 0.8%, and 3.8% [130].”
InfluentialRas mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke, W. C. M., & Heinemann, V. (2010) · PubMed · Cited by 53
Chen, J., Jin, Y., Zhai, Y., Qiong, Q., & Zhou, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10151 · Cited by 52 · cited 1×
“Multiple retrospective and prospective studies have demonstrated that high mRNA expression of AREG and EREG in primary tumors associates with superior ORR, PFS, and OS in patients receiving anti-EGFR therapy [67,68].”
Randon, G., Maddalena, G., Germani, M. M., Pircher, C. C., Manca, P., Bergamo, F., Giordano, M., Sposetti, C., Montagna, A., Vetere, G., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00037 · Cited by 52 · cited 1×
“Similarly, Randon et al. [60] reported a median PFS of 12.8 months in hyperselected RAS / BRAF WT, microsatellite-stable patients without PRESSING2 alterations, compared with only 6.8 months in those harboring PRESSING2-defined resistance drivers, showing that these additional genomic alterations…”
InfluentialPietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02026 · Cited by 51 · cited 1×
“After a median follow-up of 13.6 months, objective response rates were 30.2%, 7.5%, and 1.9%, respectively, and median OS was not reached for the 960 mg arm, 11.9 months for the 240 mg arm, and 10.3 months for the investigator’s choice [126].”
InfluentialRossini, D., Boccaccino, A., Carullo, M., Antoniotti, C., Dima, G., Ciracì, P., Marmorino, F., Moretto, R., Masi, G., & Cremolini, C. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.006 · Cited by 51 · cited 1×
“…by real-world studies, consistently show that left-sided RAS WT tumors derive substantial benefit from anti-EGFR therapy, with higher ORR (74% vs. 62%; odds ratio, 1.77; 95% CI, 1.39–2.26; p < 0.0001) and longer OS (hazard ratio, 0.77; 95% CI, 0.68– 0.88; p < 0.0001) compared to bevacizumab [37].”
InfluentialHamid, M. A., Pammer, L. M., Oberparleiter, S., Günther, M., Amann, A., Gruber, R., Mair, A., Nocera, F. I., Ormanns, S., Zimmer, K., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00892-y · Cited by 49
Vidal, J., Fernández‐Rodríguez, C., Casadevall, D., Alfonso, P. G., Páez, D., Guix, M., Alonso, V., Cano, M. T., Santos, C., Durán, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1696 · Cited by 47 · cited 1×
“The PLATFORM-B study showed that decreases in ctDNA trunk mutations at cycle 3 strongly predicted PFS (HR = 0.23, p = 0.001) [78].”
InfluentialUnveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 46 · cited 1×
“As a result, cetuximab loses its inhibitory effect [117,118].”
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 45 · cited 1×
“In the context of anti-EGFR therapy, ctDNA analysis has proven particularly valuable for three applications: (1) baseline selection for therapy initiation, (2) early assessment of treatment response, and (3) identification of candidates for rechallenge therapy [73,74].”
Rachiglio, A. M., Lambiase, M., Fenizia, F., Roma, C., Cardone, C., Iannaccone, A., De Luca, A., Carotenuto, M., Frezzetti, D., Martinelli, E., et al. (2019) · Cancers · doi:10.3390/cancers11060859 · Cited by 43 · cited 1×
“Comprehensive genomic profiling reveals that nearly half of patients with RAS / BRAF WT tumors harbor alternative resistance biomarkers when extensive panels are applied [61].”
Lee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 41 · cited 1×
“While these medications have improved survival in non-mutant KRAS WT mCRC, they are effective only in a subset of patients [56,82,83].”
Li, P., & Huang, D. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1507621 · Cited by 41 · cited 1×
“Beyond these two important cascades, EGFR signaling also engages the JAK/STAT pathway, particularly STAT3 [26], which regulates transcription of genes involved in proliferation, angiogenesis, and immune evasion [27,28].”
Snyder, L. C., Astsaturov, I. A., & Weiner, L. M. (2005) · Clinical Colorectal Cancer · doi:10.3816/ccc.2005.s.010 · Cited by 37 · cited 2×
“Both bind with high affinity to the extracellular domain III of EGFR, preventing ligand binding, blocking receptor autophosphorylation, and promoting receptor internalization and degradation [31].”
Shitara, K., Muro, K., Watanabe, J., Yamazaki, K., Ohori, H., Shiozawa, M., Yasui, H., Oki, E., Sato, T., Naito, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.4_suppl.11 · Cited by 35 · cited 1×
“Studies implementing negative hyperselection demonstrate that 24–30% of RAS / BRAF WT patients harbor at least one additional resistance alteration [58,59].”
Tardito, S., Matis, S., Zocchi, M. R., Benelli, R., & Poggi, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137131 · Cited by 34 · cited 1×
“Furthermore, several anti-EGFR antibody drug conjugates are under investigation for the treatment of CRC [151].”
Price, T., Ang, A., Boedigheimer, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Satya Suresh, A., Thomas, A., Tjulandin, S., et al. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1798695 · Cited by 33 · cited 1×
“For example, one study reported that the EGFR p.S492R mutation was absent at baseline but emerged at a rate of 1% after panitumumab therapy and 16% after cetuximab therapy [131].”
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11600-z · Cited by 33 · cited 1×
“Other biomarkers, such as BRAF mutations and other genomic or proteomic signatures, are under investigation to more precisely stratify patients and predict outcomes [11].”
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32 · cited 2×
“Patients selected through this extended molecular approach will achieve higher response rates and improved clinical outcomes [148].”
Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
Mirone, G., Shukla, A. K., & Marfè, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.012 · Cited by 32 · cited 2×
“Resistance to these inhibitors is inevitable and typically develops within 1–2 years due to multiple molecular mechanisms [17,84].”
HER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Y., Arıkan, H., & Akbulut, Ö. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03887-0 · Cited by 30 · cited 3×
“HER2 amplification is present in approximately 2–4% mCRC [62].”
InfluentialHurdles and Complexities of Codon 13 KRAS Mutations
Morelli, M. P., & Kopetz, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.6535 · Cited by 28 · cited 1×
“The discovery that RAS mutations predict resistance to anti-EGFR therapy represents a landmark achievement in precision oncology for CRC. Initially, only KRAS exon 2 (codons 12 and 13) mutations were recognized as negative predictive biomarkers [51].”
Stahler, A., Stintzing, S., Modest, D. P., Ricard, I., Gießen-Jung, C., Kapaun, C., Ivanova, B., Kaiser, F., von Weikersthal, L. F., Moosmann, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2748 · Cited by 27 · cited 1×
“Multiple retrospective and prospective studies have demonstrated that high mRNA expression of AREG and EREG in primary tumors associates with superior ORR, PFS, and OS in patients receiving anti-EGFR therapy [67,68].”
Lin, Z., Zhang, L., Zhou, J., & Zheng, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10597 · Cited by 27 · cited 1×
“Lin et al. [103] demonstrated that Smad4 loss promotes EMT and attenuates cetuximab sensitivity, while Bray et al. [104] observed increased EMT markers at the time of acquired cetuximab resistance in patient samples.”
Pietrantonio, F., Bergamo, F., Rossini, D., Ghelardi, F., Grandis, M. C. D., Germani, M. M., Barsotti, G., Formica, V., Frassineti, G. L., Boscolo, G., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113396 · Cited by 24 · cited 2×
“Studies implementing negative hyperselection demonstrate that 24–30% of RAS / BRAF WT patients harbor at least one additional resistance alteration [58,59].”
InfluentialFrank, D., Jumonville, A. J., LoConte, N. K., Schelman, W. R., Mulkerin, D. L., Lubner, S. J., Richter, K., Winterle, N., Wims, M. B., Dietrich, L. L., et al. (2012) · PubMed · doi:10.3978/j.issn.2078-6891.2011.049 · Cited by 23 · cited 1×
“In unselected patients, the use of erlotinib as maintenance treatment or the combination of lapatinib with capecitabine did not yield any significant results [133,134].”
Insulin-Like Growth Factor I Receptor Messenger RNA in the Colon Is Unchanged During Neoplasia
Zenilman, M. E., & Graham, W. (1997) · Cancer Investigation · doi:10.3109/07357909709018911 · Cited by 23 · cited 1×
“Upon its binding to its ligand, and activation of the RAS / RAF /MAPK and PI3K/AKT pathways takes place [108,109].”
Raghav, K. P. S., Guthrie, K. A., Tan, B. R., Denlinger, C. S., Fakih, M., Overman, M. J., Dasari, A. N., Corum, L. R., Hicks, L. G., Patel, M. D., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01710 · Cited by 16 · cited 1×
“…respectively), dual HER2 inhibition achieved a higher ORR of 34.6% compared to 28% respectively, noting that the patients who responded to treatment had significantly higher HER2/CEP17 ratio (14.7 vs. 6.5; p = 0.005) and gene copy number (29.7 vs. 13.2, p = 0.004) compared to non-responders [141].”
InfluentialGuernsey-Biddle, C., High, P. C., & Carmon, K. S. (2024) · Onco · doi:10.3390/onco4040019 · Cited by 14
Chowdhury, S., Gupta, R., Millstein, J., Lin, K., Haridas, V., Zeineddine, M. A. A., Parseghian, C. M., Lenz, H., Kopetz, S., & Shen, J. P. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00422 · Cited by 12 · cited 1×
“CMS2 (canonical/epithelial) tumors, characterized by WNT and MYC pathway activation, are highly EGFR dependent and consistently derive substantial benefit from anti-EGFR therapy [69,70].”
Phospholipase Cγ1 represses colorectal cancer growth by inhibiting the Wnt/β-catenin signaling axis
Shin, K. J., Jang, H., Lee, Y. J., Lee, Y. G., Suh, P., Yang, Y. R., & Chae, Y. C. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.012 · Cited by 12
de Moraes, F. C. A., Rodrigues, A. L. S. D. O., Priantti, J. N., Limachi-Choque, J., & Burbano, R. M. R. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01128-1 · Cited by 11
Zaanan, A., Bergen, E. S., Evesque, L., Meurisse, A., Artru, P., Lecomte, T., Bouché, O., Lepère, C., Ambrosini, M., Coriat, R., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf229 · Cited by 10 · cited 1×
“Similarly, in the RASINTRO study (NCT03259009) [80], anti-EGFR rechallenge in refractory disease was more effective in patients who were ctDNA RAS / BRAF WT at baseline, and especially in those showing an early molecular response (marked ctDNA decline > 50%).”
Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
Buzard, B., Douglass, L., Gustafson, B., Buckley, J. L., Roth, M., Kujtan, L. A., & Bansal, D. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i10.1829 · Cited by 9 · cited 1×
“But in patients with EGFR mutations, there are case reports that confirm the efficacy of osimertinib with responses that may last more than one year [135,136].”
Ciappina, G., Toscano, E., Ottaiano, A., Capuozzo, M., Consolo, P., Maiorana, E., Carroccio, P., Franchina, T., Ieni, A., Mauro, A. D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052216 · Cited by 9 · cited 1×
“In the context of anti-EGFR therapy, ctDNA analysis has proven particularly valuable for three applications: (1) baseline selection for therapy initiation, (2) early assessment of treatment response, and (3) identification of candidates for rechallenge therapy [73,74].”
Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Wang, L., Wei, D., Li, S., & Jiang, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03569-x · Cited by 8 · cited 1×
“These agents have shown encouraging preliminary activity and may help restore sensitivity to EGFR inhibition, particularly when used in combination with anti-EGFR therapies [152].”
Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review
Machmouchi, A., Chehade, L., Temraz, S. N., & Shamseddine, A. I. (2023) · Biomedicines · doi:10.3390/biomedicines11030678 · Cited by 8 · cited 1×
“This dual metabolic disruption may sensitize KRAS - and BRAF -mutant cells to treatment and help overcome resistance to anti-EGFR therapies [127].”
Self-citationVivas, C. S., Salva, F., Fernández‐Rodríguez, C., Alonso-Orduña, V., Losa, F., Páez, D., Vidal, J., Salud, A., Fernandez, P. R., Aguilera, M. S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.208 · Cited by 8
Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
Randon, G., & Pietrantonio, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1954 · Cited by 7 · cited 1×
“The biological rationale is that tumors with high AREG/EREG expression exhibit “EGFR addiction,” making them more dependent on EGFR signaling and consequently more sensitive to its inhibition [66].”
Germani, M. M., Vetere, G., Giordano, M., Ciracì, P., Capone, I., Tamborini, E., Conca, E., Busico, A., Pietrantonio, F., Piva, V. M., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1307545 · Cited by 7 · cited 1×
“The PARERE trial demonstrated that 34% of patients with tissue RAS / BRAF WT tumors harbored RAS / BRAF mutations in baseline ctDNA, and an additional 30% had other potential resistance alterations [77].”
Lorona, N. C., Sankar, K. N., Stern, M. C., Schmit, S. L., & Figueiredo, J. C. (2025) · Cancer Causes & Control · doi:10.1007/s10552-025-02002-6 · Cited by 7
Kim, T. W., Price, T. J., Grasselli, J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.2025.43.4_suppl.tps326 · Cited by 6 · cited 1×
“CodeBreak 301 is an ongoing phase III trial that is investigating sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab in the first-line setting [129].”
da Silva, L. F. L., Saldanha, E. F., da Conceição, L. D., Noronha, M. M., Silva, M. V., & Peixoto, R. D. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01152-1 · Cited by 5
Akkuş, E., Öksüz, N. E., & Erul, E. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104741 · Cited by 5 · cited 1×
“More recently, KRAS G12C inhibitors such as adagrasib and sotorasib, though modestly active as monotherapy in CRC, have shown enhanced efficacy when combined with anti-EGFR therapy, highlighting the expanding role of genotype-specific combinations [44].”
Abbas, N., Zahreddine, L., Tawil, A. N., Natout, M., & Shamseddine, A. I. (2024) · Diagnostics · doi:10.3390/diagnostics14222512 · Cited by 4 · cited 1×
“EMT is a complicated process where epithelial cells transform and acquire mesenchymal characteristics [99,100].”
Self-citationRaghav, K. P. S., Cutsem, E. V., Arnold, D., Oberstein, P. E., Lee, M. A., Cruz-Correa, M. R., Chen, E. X., Han, S., Malik, R. A., Eng, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.2025.43.4_suppl.197 · Cited by 4 · cited 1×
“Bispecific antibodies such as Amivantamab, which targets EGFR-MET, have demonstrated efficacy when combined with chemotherapy in right-sided CRC [150].”
Sackstein, P. E., Chintapally, N., Wilgucki, M., et al. (2023) · PubMed · Cited by 4
Morris, V. K., Quintanilha, J. C. F., Elvin, J. A., Graf, R. P., & Kopetz, S. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.2025.43.4_suppl.237 · Cited by 3 · cited 1×
“Importantly, ctDNA may detect resistance mutations present in metastatic sites but absent in the primary tumor, preventing futile anti-EGFR therapy [75,76].”
Kondo, T., Kikuchi, O., Yamamoto, Y., Sunami, T., Wang, Y., Fukuyama, K., Saito, T., Nakahara, H., Minamiguchi, S., Kanai, M., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae113 · Cited by 2 · cited 1×
“But in patients with EGFR mutations, there are case reports that confirm the efficacy of osimertinib with responses that may last more than one year [135,136].”
Closing the loop on EGFR therapy: decoding cetuximab response through circ-EGFR
Pilati, C., & Laurent‐Puig, P. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00332-1 · Cited by 1 · cited 1×
“These emerging assays may expand the scope of liquid biopsy beyond DNA mutations to RNA-based predictive tools [81].”
Cited by
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“Studies such as CRICKET and CAVE showed that restarting the same therapy in carefully selected patients can lead to increased overall survival and ORR [33].”
InfluentialDoes the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?
Raeesian, N., & Riese, D. J. (2026) · Biomolecules · doi:10.3390/biom16081079
Raut, R., Anwar, S., Alromaihi, R. A., & Alrumaihi, F. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080807
Kwiatkowska, L., & Szczuko, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177559
“Therefore, before incorporating this therapeutic strategy, it is essential to assess both the molecular status and the tumor location [42].”
Gao, J.-M., Yan, W., Yang, J., Ren, H., Zhao, L., Zhang, Y., Chen, Y., Zhou, J., Wei, Z.-Z., Liu, Q., et al. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.129000
Metadata
- Authors
- Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A.
- Affiliations
- American University of Beirut Medical Center (LB)
- Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Riad El Solh, Beirut 1107-2020, Lebanon
- Corresponding author
- Shamseddine, Ali
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-04-03
- Volume
- 27
- Issue
- 7
- Pages
- 3265
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13072906
- OpenAlex
- W7149929304
- Cited by
- 4
- References
- 135
- Citations by year
- 2026: 4
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- colorectal cancer, EGFR signaling, anti-EGFR monoclonal antibody, cetuximab, panitumumab, treatment resistance, predictive biomarkers, RAS mutations, BRAF mutation, microsatellite instability, HER2 amplification, EGFR ligands, consensus molecular subtypes, liquid biopsy, combination therapy, precision oncology, RAS/MAPK pathway, PI3K/AKT/mTOR pathway, epithelial-mesenchymal transition, molecular stratification
- MeSH terms
- Antineoplastic Agents, Immunological, Humans, Mutation, Biomarkers, Tumor, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.